These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1725072)

  • 21. Cellular immunity in patients with meningococcal disease and in vaccinated subjects.
    Greenwood BM; Oduloju AJ; Ade-Serrano MA
    Clin Exp Immunol; 1979 Oct; 38(1):9-15. PubMed ID: 118835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The implications of vaccines for prevention of bacterial meningitis.
    Riordan A
    Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.
    Litt DJ; Savino S; Beddek A; Comanducci M; Sandiford C; Stevens J; Levin M; Ison C; Pizza M; Rappuoli R; Kroll JS
    J Infect Dis; 2004 Oct; 190(8):1488-97. PubMed ID: 15378443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
    Vescia N; Mastroeni I; Pompa MG; Signorelli C; Fara GM
    Ann Ig; 1989; 1(6):1293-8. PubMed ID: 2484465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia.
    Plested JS; Harris SL; Wright JC; Coull PA; Makepeace K; Gidney MA; Brisson JR; Richards JC; Granoff DM; Moxon ER
    J Infect Dis; 2003 Apr; 187(8):1223-34. PubMed ID: 12696001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
    Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
    Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
    Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
    Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of monoclonal antibodies to Neisseria lactamica in an antigen selection to Neisseria meningitides B vaccine.
    De Gaspari EN
    Hybridoma (Larchmt); 2008 Oct; 27(5):387-93. PubMed ID: 18803504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
    Milagres LG; Gorla MC; Rebelo MC; Barroso DE
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Active immunization for prevention of meningococcal infections].
    Kardymowicz B; Rymkiewicz D
    Przegl Epidemiol; 1980; 34(2):193-201. PubMed ID: 6776590
    [No Abstract]   [Full Text] [Related]  

  • 31. Control of meningococcal meningitis with meningococcal vaccines.
    Artenstein MS
    Yale J Biol Med; 1975 Jul; 48(3):197-200. PubMed ID: 808913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines.
    Heyderman RS; Davenport V; Williams NA
    Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine against meningococcal disease.
    Narain JP; Mukherjee D
    Indian Pediatr; 1985 Jun; 22(6):405-7. PubMed ID: 3938975
    [No Abstract]   [Full Text] [Related]  

  • 34. Neisseria proteomics for antigen discovery and vaccine development.
    Christodoulides M
    Expert Rev Proteomics; 2014 Oct; 11(5):573-91. PubMed ID: 25017717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species.
    Troncoso G; Sánchez S; Moreda M; Criado MT; Ferreirós CM
    FEMS Immunol Med Microbiol; 2000 Feb; 27(2):103-9. PubMed ID: 10640604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.
    Ambrosch F; Wiedermann G; Crooy P; George AM
    Bull World Health Organ; 1983; 61(2):317-23. PubMed ID: 6407768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.
    Li Y; Zhang Q; Winterbotham M; Mowe E; Gorringe A; Tang CM
    Infect Immun; 2006 Nov; 74(11):6348-55. PubMed ID: 16966413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune response to meningococci].
    Flaegstad T
    Tidsskr Nor Laegeforen; 1989 Jan; 109(1):33-6. PubMed ID: 2492123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccines against Neisseria meningitidis].
    Ferrón L; Criado MT; Ferreirós CM
    Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.